Podcasts about antipsychotics

What kind of man gets studied at Yale, Brown, and Harvard, builds a 300 person international research consortium, and still has powerful people working to erase his name? Dr. Daniel Ingram is not a guru. He is a retired level one trauma emergency physician. A published neuroscience researcher. The author of a book that has shaped contemplative practice for tens of thousands of readers. The acting organizer of a global research effort spanning Harvard, Yale, Brown, Cambridge, and Oxford. By every credential medicine respects, he is one of their own.So why did a senior figure allegedly commission an academic article engineered to surface at the top of every search of his name, with one stated goal? That nobody would ever believe him again. Because Dr. Ingram crossed a line his profession does not permit. He claimed that awakening is real. That it is measurable. That it is observable in the brain.  We go into what he has seen at the edges of human perception. What he documented in the lab. What he believes medicine is doing to patients every single day by refusing to look.The Emergent Phenomenology Research Consortium

The Psych Review recorded this episode on the final evening of the 2026 RANZCP Congress. Alanna, Milla, and Mazz take us through their highlights. Milla thoughtfully reflects on the mindfulness workshop she attended, Alanna was moved by an experience of the intersection between psychiatry and the arts, and Mazz attended an action packed workshop covering the use of antipsychotic medications in mood states.As we attended workshops and talks for this session we do not have any specific references to share!The Psych Review was brought to you by Call to Mind, a telepsychiatry service that you can learn more about at www.calltomind.com.au. The original music in our podcast was provided by the very talented John Badgery, and our logo was designed by the creative genius of Naz.

Welcome to PsychEd, the psychiatry podcast for medical learners, by medical learners. This short episode covers the basics of extrapyramidal symptoms.Hosts: Jo Kikukawa (MS2)Dr. Matthew Cho (PGY1)Sena Gok (Scientist) Audio Editing: Dr. Matthew Cho (PGY1)References:Dayalu, P., & Chou, K. L. (2008). Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opinion on Pharmacotherapy, 9(9), 1451–1462. https://doi.org/10.1517/14656566.9.9.1451Drake, R. E., & Ehrlich, J. (1985).Suicide attempts associated with akathisia. American Journal of Psychiatry, 142(4), 499–501. https://doi.org/10.1176/ajp.142.4.499Pringsheim, T., Gardner, D., Addington, D., Martino, D., Morgante, F., Ricciardi, L., Poole, N., Remington, G., Edwards, M., Carson, A., & Barnes, T. R. E. (2018). The assessment and treatment of antipsychotic-induced akathisia. Canadian Journal of Psychiatry, 63(11), 719–729. https://doi.org/10.1177/0706743718760288Poyurovsky, M., Pashinian, A., Weizman, R., Fuchs, C., & Weizman, A. (2006). Low-dose mirtazapine: A new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. Biological Psychiatry, 59(11), 1071–1077. https://doi.org/10.1016/j.biopsych.2005.11.004Links to Scales Featured in Episode:https://simpleandpractical.com/wp-content/uploads/2014/09/Barnes-Akathisia-Rating-Scale-BARS.pdfhttps://www.psychdb.com/_media/meds/antipsychotics/sas_simpson_angus_scale_modified.pdfhttps://www.ohsu.edu/sites/default/files/2019-10/%28AIMS%29%20Abnormal%20Involuntary%20Movement%20Scale.pdfFor more PsychEd, follow us on Instagram (⁠⁠⁠@psyched.podcast⁠⁠⁠), Facebook (⁠⁠⁠PsychEd Podcast⁠⁠⁠), X (⁠⁠⁠@psychedpodcast⁠⁠⁠), and Bluesky (⁠⁠⁠@psychedpodcast.bsky.social‬⁠⁠⁠). You can email us at ⁠⁠⁠psychedpodcast@gmail.com⁠⁠⁠ and visit our website at⁠⁠⁠ psychedpodcast.org⁠⁠⁠.

In this episode, we explore KarXT, a newly FDA-approved antipsychotic with a groundbreaking cholinergic mechanism, through the lens of a single powerful metric: the Number Needed to Treat. Could an NNT of 5 change how you approach treatment-resistant schizophrenia? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 80 How Effective Is KarXT (Xanomeline-Trospium) for Schizophrenia? NNT and NNH Explained

In this episode, Dr. Puder sits down with Franciska de Beer, MSc, first author of landmark HAMLETT-OPHELIA Consortium papers in JAMA Psychiatry, World Psychiatry, and Psychological Medicine. They dive deep into the psychiatrist effect in first-episode psychosis, revealing that individual psychiatrists explain approximately 10% of variance in positive symptom improvement and daily functioning, even after controlling for medication dose. The conversation explores groundbreaking HAMLETT findings on early antipsychotic tapering versus maintenance, dopamine supersensitivity after high-affinity D2 blockers, sex differences in treatment outcomes and clozapine levels during menopause, and why shared decision-making and reflective functioning matter more than ever in psychosis care.   By listening to this episode, you can earn 1.25 Psychiatry CME Credits. Link to blog Link to YouTube video

Patients around the world have been discovering that the psychiatric drug their doctor or psychiatrist started them on years ago is now hijacking their lives, causing a plethora of unwanted side effects. For instance, antidepressant drugs have many potential damaging effects, including mania, violence, aggression, irritability, apathy, persistent sexual dysfunction, and a suppression of feelings of love. Antipsychotic drugs (now frequently prescribed as “sleep aids” and “antidepressants”) can cause cognitive dysfunction, including disabling “brain fog,” apathy, and physical disabilities, including the permanent movements of Tardive Dyskinesia and other debilitating conditions.

In this episode of Look Again: Mental Illness Re-examined, we explore recovery beyond medical definitions and diagnoses. Host Faydra Aldridge introduces a new era of the podcast which now available in both audio and video by bringing listeners face-to-face with two powerful stories. Matthew shares his decades-long journey to remission, the role medication and reflective self-work have played in his life, and how purpose fuels his advocacy through Mind Aid. Abigail offers a different path, one that includes sobriety, shifting diagnoses, daily self-care, and learning to live well while still managing symptoms. Together, their stories challenge stigma and remind us that recovery isn’t one-size-fits-all. It’s personal, evolving, and deeply human.Timecodes:(01:05) What recovery really means (not what you think)(03:08) The moment schizophrenia hit(05:20) The medication that changed everything(07:30) The day Matthew's symptoms suddenly stopped(08:40) Recovery vs cure (10:10) Why Matthew refuses to stop medication(12:49) “You still get to write your story”(14:03) Breaking the stigma around schizophrenia(15:20) What recovery really looks like(16:14) 27 months sober: Abigail’s story(17:30) Years of misdiagnosis(18:45) What schizophrenia actually feels like(20:00) The daily habits that keep Abigail stable(21:34) Why recovery is still possibleSee omnystudio.com/listener for privacy information.

Second-generation (also known as atypical) antipsychotics are increasingly used as adjunctive therapy for patients with major depressive disorder who have an inadequate or partial response to antidepressants. This course reviews the clinical rationale for their use, highlights newly approved options, and examines key safety, efficacy, and monitoring considerations. You will gain practical guidance to support patient selection, counseling, and shared decision-making when these agents are incorporated into depression management.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTSarah Grady, PharmD, BCPS, BCPPProfessor of Pharmacy Practice, Clinical PharmacistDrake University/Broadlawns Medical CenterPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members only.To learn more about Health Mart, click here: https://join.healthmart.com/PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Explain the role of second-generation (atypical) antipsychotics as adjunctive therapy in the management of major depressive disorder.2. Identify pharmacist-relevant considerations for counseling, monitoring, and risk benefit assessment when second-generation antipsychotics are used for depression.Rachel Maynard and Sarah Grady have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-26-059-H01-PInitial release date: 3/16/2026Expiration date: 3/16/2027Additional CPE details can be found here.

Second-generation (also known as atypical) antipsychotics are increasingly used as adjunctive therapy for patients with major depressive disorder who have an inadequate or partial response to antidepressants. This course reviews the clinical rationale for their use, highlights newly approved options, and examines key safety, efficacy, and monitoring considerations. You will gain practical guidance to support patient selection, counseling, and shared decision-making when these agents are incorporated into depression management.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTSarah Grady, PharmD, BCPS, BCPPProfessor of Pharmacy Practice, Clinical PharmacistDrake University/Broadlawns Medical CenterGET CE FOR THIS LISTENING!The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that's less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the GameChangers Clinical Update Series. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Explain the role of second-generation (atypical) antipsychotics as adjunctive therapy in the management of major depressive disorder.2. Identify pharmacist-relevant considerations for counseling, monitoring, and risk benefit assessment when second-generation antipsychotics are used for depression.Rachel Maynard and Sarah Grady have no relevant financial relationships to disclose.0.05 CEU/0.5 HrUAN: 0107-0000-26-059-H01-PInitial release date: 3/16/2026Expiration date: 3/16/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

A board-certified psychiatrist trained at one of the most prestigious psychiatric institutions in the world was fired for refusing to put a young woman on medication after the last prescription nearly killed her. Dr. Aruna Nammi left the system and built something radically different, combining functional medicine with 5,000-year-old Ayurvedic wisdom to reverse conditions psychiatry calls chronic and incurable. We go deep on why depression is a disconnection syndrome, the three root causes of all disease, what ancient traditions understood about psychosis that modern psychiatry ignores, and the shift in consciousness that may be unfolding on this planet right now.Trinergy Health Website Visit Center for Integrated Behavioral HealthDr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / XSubstack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically GenuineConscious Clinician CollectivePLEASE SUPPORT OUR PARTNERS15% Off Pure Spectrum CBD (Code: RadicallyGenuine)10% off Lovetuner click here

In this episode, we break down antipsychotic medications—how they work, when they're used, and what you need to know. From mechanisms of action to key side effects and clinical considerations, we simplify a complex topic into clear, practical knowledge you can actually use.

In this episode, Dr. Andy Cutler speaks with Dr. Jonathan Meyer to dispel common myths about antipsychotic treatment, from concerns about sedation, personality change, and brain effects to misunderstandings about safety, long-acting injectables, and clozapine. The discussion focuses on what the evidence actually shows about efficacy, risk, and recovery, and how clinicians can communicate more clearly and confidently with patients and families.  Jonathan Meyer, MD, DLFAPA, is a Voluntary Clinical Professor of Psychiatry at the University of California, San Diego. He serves as a Senior Academic Advisor to the California Department of State Hospitals, is a psychopharmacology consultant to the first episode psychosis program at Balboa Naval Medical Center, and has published extensively on psychopharmacology, including co-authoring The Clozapine Handbook, The Clinical Use of Antipsychotic Plasma Levels, and The Lithium Handbook with Dr. Stephen Stahl.  Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and EMA Wellness. He is a Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Save $100 on registration for 2026 NEI Spring Congress with code NEIPOD26  Register today at nei.global/spring  Never miss an episode!

In this episode, we explore how GLP-1 agonists—the weight loss medications making headlines everywhere—could revolutionize management of antipsychotic-induced weight gain. Can these drugs help patients lose weight while maintaining psychiatric stability? We examine the latest evidence and discuss practical implementation strategies for your practice. Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 76 Antipsychotic-Induced Weight Gain: Are GLP-1 Agonists Effective?

Show notes at pharmacyjoe.com/episode1097 In this episode, I'll discuss whether ICU patients benefit from daily QTc interval monitoring during antipsychotic use for delirium.

Send a Text to the Moms - please include your contact info if you want a response. thanks!Weight gain is one of the most common—and distressing—side effects of antipsychotic medications. For many people, it affects self-esteem, physical health, and even the willingness to stay on treatment. In this episode of Schizophrenia: Three Moms in the Trenches, we talk about why these medications cause weight gain, whether it can be treated or prevented, and what families should understand about metabolism and insulin resistance. We also touch on the growing conversation around the ketogenic diet and its possible role in treatment. What's evidence-based, what's still emerging, and how can families advocate wisely?  Guest :  Robert S Laitman, MD, is an internal medicine physician at Bronx Westchester Medical Group in New York. Book: MEANINGFUL RECOVERY from Schizophrenia and Serious Mental Illness with Clozapine: Hope & Help BUY THE 5th EDITION - for an extensive update to Dr Laitman's section, An Optimistic Nephrologist. MoreIn depth data about clozapine and the mitigation of side effects for a MEANINGFUL RECOVERY.Published in December 2025.We also touch on the expanding reach of Doromind, so more can benefit from Dr. Laitman's treatment protocols.https://www.doromind.com/Keto Diet resources:https://accordmh.com/Dr. Chris Palmer has written books about it.Want to know more?Join our facebook page Our websites:Randye KayeMindy Greiling Miriam (Mimi) Feldman

What Would It Take to Lose Every Civil Right You Have? Not a trial. Not a conviction. Not evidence of a crime.In America, all it takes is one person's opinion—dressed up in medical language and backed by institutional authority.Rachel Hunter walked into a hospital for a routine check. She walked out 38 days later, having been transferred between multiple psychiatric facilities, forcibly injected with antipsychotics, and stripped of her autonomy—all without her consent. Her crime? She'd been baptized. She felt at peace. She prayed for her neighbors. In this episode, Rachel shares what happened when a spiritual awakening was reinterpreted as a psychiatric emergency—and what she discovered when she started investigating the system that imprisoned her. This is a story about how easily your freedom can disappear. And about one woman who refused to stay silent. If you think this couldn't happen to you or someone you love, this episode will change your mind. Listen. Then share it with someone who needs to hear it. Visit Center for Integrated Behavioral HealthDr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / XSubstack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically GenuineConscious Clinician CollectivePLEASE SUPPORT OUR PARTNERS15% Off Pure Spectrum CBD (Code: RadicallyGenuine)10% off Lovetuner click here

In this episode, we explore a new study examining whether antidepressants and antipsychotics truly increase the risk of torsades de pointes, a potentially fatal cardiac arrhythmia. What does the evidence say about using multiple psychiatric medications together, and when should we actually be concerned? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 75 Torsades de Pointes: Impact of Antidepressants and Antipsychotics

Army veteran Angie Peacock survived Iraq in 2003, only to become a prisoner of psychiatric torture. Between VA and civilian psychiatrists, she was prescribed 18 psychiatric drugs at once, then cold-turkeyed off benzodiazepines—leaving her unable to walk for 2.5 years and suicidal for three straight years.After losing 20 years to psychiatric "treatment," Angie escaped and has since helped over 1,000 people navigate psychiatric drug withdrawal. In this explosive conversation, she exposes how both military and civilian psychiatry systematically poison patients, why asking for help destroyed her military career, and delivers a radical truth: the mental health system isn't broken—it's designed to create lifelong patients.For anyone trapped in psychiatric dependency or questioning their "treatment resistant" label, this episode proves you're not crazy. They are. Visit Center for Integrated Behavioral HealthDr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / XSubstack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically GenuineConscious Clinician CollectivePLEASE SUPPORT OUR PARTNERS15% Off Pure Spectrum CBD (Code: RadicallyGenuine)10% off Lovetuner click here

In this episode, we explore a groundbreaking Mayo Clinic algorithm that revolutionizes antipsychotic selection for first-episode psychosis. Should the presence of violence completely change your medication choice strategy? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 75 Schizophrenia Algorithm: Selecting an Antipsychotic for First Episodes

In this episode, we challenge conventional prescribing by exploring why lithium should be the first-line treatment for acute classic mania, despite widespread use of antipsychotics. Dr. David Osser presents evidence-based arguments for lithium's unique neuroprotective benefits and long-term efficacy. Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.5 CME: An Update on Bipolar Mania Algorithm Lithium for Bipolar Mania Without Mixed Features

What dangerous secrets lie beneath the "comforting newborn smell" of one of the most trusted companies in the world?In this explosive episode, Pulitzer Prize-nominated NYT journalist Gardiner Harris pulls back the curtain on Johnson & Johnson's history, detailed in his book No More Tears: The Dark Secrets of Johnson & Johnson.Gardiner reveals J&J's systemic deception, from knowingly selling asbestos-contaminated baby powder for seven decades to marketing drugs as cancer cures that were actually "Miracle Grow" for tumours. He exposes J&J's hidden role in the opioid crisis and their shocking refusal to share life-saving HIV drugs with Africa, costing millions of lives.Drawing from years of investigative reporting, Gardiner explains how corporate PR, media influence, and medical incentives allow giants like J&J to evade accountability, even with secret Grand Jury testimony as evidence. Tara and Gardiner also discuss the stories that didn't make it into the book and the mental toll of exposing the truth.Tune in for an essential, eye-opening conversation that forces consumers to question the products of a company they love and trust.Upcoming Bound RetreatsImmersive, one-of-a-kind literary experiences that take writers into the heart of India's most breathtaking landscapes.Wiling: A Weekend Writing Retreat | 28-30 November, 2025Learn more: https://boundindia.com/retreats/ Apply to all retreats: http://bit.ly/44TzYpY ‘Books and Beyond with Bound' is the podcast where Tara Khandelwal and Michelle D'costa uncover how their books reflect the realities of our lives and society today. Find out what drives India's finest authors: from personal experiences to jugaad research methods, insecurities to publishing journeys. Created by Bound, a storytelling company that helps you grow through stories. Follow us @boundindia on all social media platforms.

Welcome to PsychEd, the psychiatry podcast for medical learners, by medical learners. This episode covers metabolic monitoring for patients on antipsychotic medications.Hosts: Grant Yao (MS4) and Dr. Angad Singh (PGY2)Audio editing: Dr. Angad Singh (PGY2)Timestamps:(0:21) - Background(2:22) - Monitoring for metabolic side effects(6:16) - Managing metabolic side effects(9:50) - SummaryReferences:Agarwal, S. M., Stogios, N., Faulkner, G. E., & Hahn, M. (2023). Pharmacological interventions for the prevention of antipsychotic-induced weight gain in people with schizophrenia: A Cochrane systematic review and meta-analysis. Schizophrenia Bulletin, 49(4), 833-835.Carolan, A., Hynes-Ryan, C., Agarwal, S. M., Bourke, R., Cullen, W., Gaughran, F., ... & O'Donoghue, B. (2024). Metformin for the prevention of antipsychotic-induced weight gain: guideline development and consensus validation. Schizophrenia bulletin, sbae205.Cooper, S. J., Reynolds, G. P., With expert co-authors (in alphabetical order):, Barnes, T. R. E., England, E., Haddad, P. M., ... & Smith, J. (2016). BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. Journal of Psychopharmacology, 30(8), 717-748.DeJongh, B. M. (2021). Clinical pearls for the monitoring and treatment of antipsychotic induced metabolic syndrome. Mental Health Clinician, 11(6), 311-319.Stogios, N., Humber, B., Agarwal, S. M., & Hahn, M. (2023). Antipsychotic-induced weight gain in severe mental illness: risk factors and special considerations. Current Psychiatry Reports, 25(11), 707-721.For more PsychEd, follow us on Instagram (⁠@psyched.podcast⁠),  Facebook (⁠PsychEd Podcast⁠), X (⁠@psychedpodcast⁠), and Bluesky (⁠@psychedpodcast.bsky.social‬⁠). You can email us at ⁠psychedpodcast@gmail.com⁠ and visit our website at⁠ ⁠⁠psychedpodcast.org⁠.

Contributor: Taylor Lynch, MD Educational Pearls: Delusional parasitosis is a subtype of the psychiatric condition delusional disorder Defined as a fixed, false belief of infestation by parasites or other organisms A somatic type of delusional disorder Primary delusional parasitosis Occurs in the absence of other psychiatric or medical conditions Secondary delusional parasitosis Causes include methamphetamine use disorder, schizophrenia, neurologic diseases, or medical conditions such as thyroid disease Pathophysiology Poorly understood Upregulation of striatal dopamine system is implicated Management Form a strong therapeutic alliance and do not discredit the patient immediately Perform a full physical exam This helps reassure the patient and strengthen the therapeutic alliance Some day there may be a patient in whom this is not a delusion Treatment & Management Discontinuation of substances if substance-induced Antipsychotic medications like risperidone or olanzapine References Lepping P, Russell I, Freudenmann RW. Antipsychotic treatment of primary delusional parasitosis: systematic review. Br J Psychiatry. 2007;191:198-205. doi:10.1192/bjp.bp.106.029660 Moriarty N, Alam M, Kalus A, O'Connor K. Current Understanding and Approach to Delusional Infestation. Am J Med. 2019;132(12):1401-1409. doi:10.1016/j.amjmed.2019.06.017 Skelton M, Khokhar WA, Thacker SP. Treatments for delusional disorder. Cochrane Database Syst Rev. 2015;2015(5):CD009785. Published 2015 May 22. doi:10.1002/14651858.CD009785.pub2 Summarized and Edited by Jorge Chalit, OMS4 Donate: https://emergencymedicalminute.org/donate/

In this episode, we explore a compelling comparison between olanzapine and risperidone for managing behavioral symptoms in dementia patients. Are the delusions we see in Alzheimer's disease actually true delusions, or something entirely different that requires a new treatment approach? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 73 Alzheimer's Disease: Olanzapine vs. Risperidone for BPSD

In this episode, Dr. Andy Cutler interviews Dr. Peter Weiden about when and how to switch antipsychotics in schizophrenia, tackling both the pitfalls and opportunities clinicians face in practice. They also explore how xanomeline–trospium has opened the door to treatments beyond dopamine and what this shift means for the future of care.  Peter J. Weiden, MD, is a psychiatrist and internationally recognized expert in the pharmacologic treatment of schizophrenia. His research and clinical work have focused on antipsychotic effectiveness, switching strategies, and medication adherence, with a particular emphasis on optimizing long-term outcomes for patients.   Andrew J. Cutler, MD, is a distinguished psychiatrist and researcher with extensive experience in clinical trials and psychopharmacology. He currently serves as the Chief Medical Officer of Neuroscience Education Institute and holds the position of Clinical Associate Professor of Psychiatry at SUNY Upstate Medical University in Syracuse, New York.  Never miss an episode!

Womanhood Wellness is where functional medicine meets feminine wisdom—guiding you to balance hormones, awaken libido, and prepare for pregnancy with intention. Join todayWhat if the hormone blocking your ovulation is the same one draining your desire?This episode is all about prolactin… a hormone made by the pituitary gland that plays a key role in breastfeeding. We get into how high prolactin can impact fertility, libido, and even dopamine, and why stress, sleep, exercise, and certain medications push it out of balance. There are natural ways to bring prolactin back into range, from nutrients like B6 and magnesium to lifestyle shifts. This is the hormone no one's talking about, but everyone should understand.You'll Learn:[00:00] Introduction[03:52] The surprising role prolactin plays in fertility, libido, and postpartum health[06:29] The push-pull between prolactin and dopamine that impacts desire and motivation[10:08] Why ADHD symptoms often worsen postpartum when prolactin rises[12:33] How high prolactin can block ovulation, your body's natural “birth control”[14:04] How elevated prolactin shortens luteal phases and lowers progesterone[15:30] Hidden triggers of prolactin imbalance[23:44] The critical lab-testing tip that prevents false high prolactin results[26:09] How nutrient deficiencies and marijuana use can silently drive prolactin higher[28:09] Symptoms that reveal a prolactin problem[35:38] Prolactin's purposeful role in suppressing sex drive during breastfeeding[38:17] How modern lifestyle stressors mimic postpartum and confuse prolactin levels[55:20] Natural supports that bring prolactin back in balanceFind more from Dr. Leah:Dr. Leah Gordon | InstagramDr. Leah Gordon | WebsiteDr. Leah Gordon | WebsiteFind more from Dr. Morgan:Dr. Morgan MacDermott | InstagramDr. Morgan MacDermott | WebsiteUse code HEALTHYMOTHER and save 15% at RedmondFor 20% off your first order at Needed, use code HEALTHYMOTHERSave $260 at Lumebox, use code HEALTHYASAMOTHER

In this episode, we explore groundbreaking research showing how long-acting injectable antipsychotics can literally save lives in schizophrenia treatment. Could choosing the right medication delivery method be the difference between a patient thriving or facing premature death by 15-20 years? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Quick Take Vol. 73 Long-Acting Injectables: Superior for Reducing Mortality in Schizophrenia?

When a company's values don't match its actions, the impact can be devastating. Kim and Amy speak with investigative journalist Gardiner Harris about his book, No More Tears: The Dark Secrets of Johnson & Johnson. Harris uncovers how a company once seen as the gold standard of integrity used its famous “Credo” to build emotional trust while covering up harmful practices—from baby powder linked to cancer to its role in the opioid crisis. The conversation goes beyond one company, raising bigger questions about accountability, transparency, and the systems meant to keep us safe. It's a candid look at how misplaced trust can cause lasting damage—and what it really takes to create a culture where honesty and responsibility come first. Get all of the show notes at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠RadicalCandor.com/podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Episode Links:⁠⁠⁠⁠⁠⁠⁠⁠⁠ Gardiner Harris No More Tears: The Dark Secrets of Johnson & Johnson  The Weekly | A Secret Opioid Memo That Could Have Slowed an Epidemic | The New York Times A Devastating New Exposé of Johnson & Johnson Indicts an Entire System | The New Republic The Johnson & Johnson Cancer Drug Scandal That Encapsulates Corruption In Health Care | STAT News J&J Is Back On The Legal Warpath After Striking Out In Baby Powder Bankruptcy | Reuters Antipsychotic Drugs and Nursing Home Residents: What Do the Different Numbers Mean? | Center for Medicare Advocacy Empire of Pain: The Secret History of the Sackler Dynasty The Least of Us: True Tales of America and Hope in the Time of Fentanyl and Meth  Physician Payments Sunshine Act (also known as the Open Payments program) Watch Cold Case: The Tylenol Murders | Netflix  Connect: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Website⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠TikTok⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Bluesky⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Chapters: (00:00:00) Introduction Kim and Amy introduce Gardiner Harris, investigative journalist and author. (00:01:01) No More Tears Why Gardiner's book hasn't been widely covered by the media. (00:07:35) Hidden Dangers of Products Overview of Johnson & Johnson's vast range of dangerous products. (00:15:13) Antipsychotics in Nursing Homes How antipsychotics were pushed to sedate elderly patients. (00:16:58) Opioids & Corporate Responsibility The role Johnson & Johnson played in the opioid epidemic. (00:24:04) The Power of Branding & Emotional Trust The exploitation of emotional branding to avoid accountability. (00:27:28) Incentives, Conflicts, & Complicity How financial incentives corrupted doctors, researchers, and hospitals (00:39:12) Breaking Points & Speaking Up Stories about the individuals affected by Johnson & Johnson. (00:47:27) The Cult of the Credo How J&J weaponized its corporate credo to silence whistleblowers. (00:52:19) How J&J Got Away With It The ways J&J avoided accountability and hid decades of misconduct. (00:57:36) Tylenol, Safety, & the Illusion of Trust The FDA's inability—or unwillingness—to enforce safety despite evidence. (01:03:29) Hope, Oversight & Individual Action How individual action and awareness can drive systemic change. (01:08:10) Conclusion Learn more about your ad choices. Visit megaphone.fm/adchoices

These are all my antipsychotic stories that I have uploaded to my channel the past few years. Made a compilation in case some of you missed some!

Meds that require special skill to start: Antipsychotics, Cobenfy, and a research update on antidepressant metabolism in Asians.CME: Take the CME Post-Test for this EpisodePublished On: 08/11/2025Duration: 12 minutes, 19 secondsChris Aiken, MD and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this episode, we explore groundbreaking research on managing antipsychotic-induced weight gain through a comprehensive network meta-analysis. Could the combination of low-dose metformin and lifestyle modifications be the game-changer that helps patients maintain both mental stability and physical health? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 71 Antipsychotic-Induced Weight Gain: Best Management Strategies

Welcome Back! We have recently partnered with Psych Congress to bring our audience access to some of their leading speakers and educators, and today is the second installment of this endeavor, featuring Dr. Jonathan Meyer on the topic of Antipsychotic plasma level monitoring. Dr. Meyer has authored the handbook on this topic, along with the Lithium and Clozapine handbooks as well. You can find them here: https://www.amazon.com/s?k=jonathan+meyer&crid=3IARW0R4T9RGD&sprefix=jona%2Caps%2C369Psych Congress Discount Code: PSYCHROUNDSConference Website: https://www.hmpglobalevents.com/psych-congressSources:- https://www.cambridge.org/core/books/clinical-use-of-antipsychotic-plasma-levels/E7C0B6DBB4F6031F4D47935154CBEC8D

Podcast summary of articles from the June 2025 edition of the Journal of Emergency Medicine from the American Academy of Emergency Medicine.  Topics include Artificial Intelligence in X ray interpretation, metoclopramide, antipsychotics, stroke treatment, carbon monoxide toxicity, and organophosphate toxicity.  Guest speaker is Dr. John Bennison.

In this episode, we explore the surprising link between antipsychotic medications and pneumonia risk. Did you know that pneumonia is the fourth leading cause of death in schizophrenia patients, and certain medications increase this risk in unexpected ways? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 71 Pneumonia in Schizophrenia: Which Antipsychotics Pose the Highest Risk for?

Concerned about screen time—both your kids' and your own? Perhaps you're navigating the decision of when to give your child a phone, or maybe you're rethinking past choices. While we all strive for improvement in managing screen time, our aim isn't to condemn technology or advocate for device-free living.Today, we welcome Dr. Ryan Sultan, an internationally recognized, double board-certified psychiatrist who directs the Sultan Mental Health Informatics and Adaptation Lab at Columbia University. Dr. Sultan offers expert guidance on discussing algorithms and short-form content with your children, fostering independent thinking. We'll also delve into the spread of misinformation and reactionary content, as well as the correlation between screen time and depression. Tune in for his practical advice on immediate steps you can take to help your kids gain better control over their screen time, even if they're already knee deep.(00:00:58) Welcome Dr. Ryan Sultan to the podcast.(00:04:25) If you only get one thing out of this conversation, THIS is it.(00:09:28) What is actually happening in the brain when we're using our phones? (00:15:27) Talking to our kids about algorithms.(00:21:20) When to introduce screens to kids and what age to give a phone.(00:26:16) Neurodivergence and devices: a higher risk group.(00:30:12) Heavy social media use and depression, anxiety,and suicidal ideation.(00:33:31) Multiplayer video games: are they social media?(00:36:10) Setting boundaries: a medium between doing nothing and taking it all away.(00:43:28) Sultan Lab Big Data for social media and mental health guidelines.(00:48:18) Parents, we need regulation and it's NOT impossible.(00:53:42) Summary and what to implement in your household right now to get better control over screen time.(00:56:00) Where to find Dr. Ryan Sultan. Integrative Psychiatry is a psychiatry practice that takes a holistic, collaborative approach to mental health care. The Columbia-trained clinical team provides expert, evidence-based treatment for ADHD, anxiety, depression, substance use, eating disorders, and other mental health conditions. The clinicians combine psychotherapy, research-supported psychotropic medications, and expertise as adult, adolescent, and child psychiatrists to deliver patient-centered care that meets each individual's unique needs—supporting long-term mental well-being and overall wellness.The practice is led by Dr. Ryan Sultan, an internationally recognized, double board-certified psychiatrist. He also serves as an Assistant Professor of Clinical Psychiatry at Columbia University, where he leads the Sultan Mental Health Informatics and Adaptation Lab.To learn more, visit Integrative Psychiatry or Sultan Lab. References:Sultan, R. S. (2017). Off-Label Prescribing of Antipsychotics for Youths: Who Should Be Treated? Psychiatric Times, 34(9), 26.Sultan, R. S., Liu, S. M., Hacker, K. A., & Olfson, M. (2021). Adolescents with Attention-Deficit/Hyperactivity Disorder: Adverse Behaviors and Comorbidity. Journal of Adolescent Health, 68(2), 284-291.Sultan, R. S., Saunders, D. C., & Veenstra-VanderWeele, J. (2025). Protective Effects of ADHD Medication on Real-World Outcomes. JAMA Psychiatry.Want to leave the TTSL Podcast a voicemail? We love your questions and adore hearing from you. https://www.speakpipe.com/TheThickThighsSaveLivesPodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The CVG Nation app, for ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠iPhone⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The CVG Nation app, for Android⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Fitness FB Group⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Thick Thighs Save Lives Workout Programs⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Constantly Varied Gear's ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Workout Leggings⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Is it really treatment-resistant depression or are we using the wrong treatments?In this episode, Dr. Bret Scher is joined by psychiatrist Dr. Georgia Ede to examine a new large, population-based analysis on the use of antipsychotics versus third-line antidepressants in people diagnosed with treatment-resistant depression, and what effect that has on suicide risk.They discuss:What treatment-resistant depression actually meansWhy so many people fall into this categoryThe surprising data on suicide risk and all-cause mortalityThe metabolic side effects of antipsychotic medicationsAlternative options beyond antipsychotics—including ketogenic therapy and other metabolic strategiesThis conversation explores why conventional approaches may fall short, and how metabolic psychiatry offers promising, low-risk alternatives.

A grandmother in Oklahoma is arrested after police say she drugged her grandchildren and locked them in a dog cage. R. Kelly suffers an anxiety drug overdose in a North Carolina federal prison, after claiming officials plotted to have him murdered. Drew Nelson reports.See omnystudio.com/listener for privacy information.

Is one of the most “trusted” names in healthcare responsible for millions of deaths? This explosive interview may change everything you thought you knew about the medical system. In this eye-opening episode of The Dr. Josh Axe Show, Dr. Axe sits down with Pulitzer-nominated investigative journalist and former New York Times correspondent Gardiner Harris to expose the dark underbelly of Big Pharma—specifically the disturbing history of Johnson & Johnson. Gardiner, who has reported from the White House and covered the pharmaceutical industry for decades, joins the show to discuss revelations from his groundbreaking new book No More Tears. Drawing from sealed court documents, grand jury transcripts, and firsthand reporting, he reveals how corporate greed, government collusion, and media silence have fueled some of the deadliest medical conspiracies in American history. In this episode, you'll discover: Why Johnson & Johnson may be responsible for up to 2 million deaths—and how it was covered up. How Risperdal was marketed illegally to elderly patients, despite deadly side effects. Shocking misuse of EPO in cancer patients and the hidden studies that exposed it. The FDA's role in enabling decades of pharmaceutical harm. How Tylenol became one of the most dangerous over-the-counter drugs in America. Why many “late onset schizophrenia” diagnoses in nursing homes are completely fabricated. The frightening financial ties between drug companies, academic institutions, and your doctor. Don't miss this powerful conversation that could change how you view medicine, media, and the modern healthcare system. Whether you've suspected something was off or you're just beginning to question the mainstream narrative, this episode will arm you with truth—and hope. Watch now to uncover how to protect your health, your family, and your future. #johnsonandjohnson #healthcare #draxe ------  0:00 Introduction 5:15 Corruption in American Healthcare 16:27 The Use of Antipsychotics for Nursing Home Patients 20:44 EPO for Cancer Patients 28:08 Medical Industry as Goliath  37:50 Medical Advisory Committee: FDA 42:00 Acetaminophen Side Effects  ------  Want more of The Dr. Josh Axe Show? Subscribe to the YouTube channel. Follow Dr. Josh Axe Instagram Twitter Facebook TikTok Website Follow Gardiner Harris Twitter Website ------  Staying healthy in today's world is an upstream battle. Subscribe to Wellness Weekly, your 5-minute dose of sound health advice to help you grow physically, mentally, and spiritually. Every Wednesday, you'll get:  Holistic health news & life-hacks from a biblical world view Powerful free resources including classes, Q&As, and guides from Dr. Axe The latest episodes of The Dr. Josh Axe Show Submit your questions via voice memo to be featured on the show → speakpipe.com/drjoshaxe  ------  Links:  Check out Gardiner Harris' new book, NO MORE TEARS: The Dark Secrets of Johnson & Johnson → https://www.goodreads.com/book/show/216247552-no-more-tears

In this episode, we explore the potential role of the probiotic Akkermansia muciniphila in managing olanzapine-induced weight gain. Could this tiny gut bacterium be the key to maintaining metabolic health while on antipsychotics? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 67 Olanzapine-Induced Weight Gain: Can Akkermansia Muciniphila Help?

In this episode, we discuss Autism and Education. We explore some current condition within education and some personal experiences. Specifically, the school day is in complete conflict with Autism- both Criteria A and B. This is the primary factor with the challenges of Autism in Education. The classroom requires a Social Dynamic, a Speech and Language Dynamic, and Sensory-Processing Dynamic, which is 3 strikes against Autism. In addition, the subject switching throughout the school day complicates our path of learning- Our learning style prefers spending extended times on a single subject. Autism gives us the ability to be comfortable within ourselves and this accelerates our learning, our Superpowers. School and the world mostly requires the social communication and interaction. Antipsychotics https://www.marketresearchfuture.com/reports/antipsychotic-drugs-market-2784#:~:text=The%20antipsychotic%20drugs%20market%20size,period%20(2023%20%2D%202030). Pediatrician and Psychologists on the Medical Paradigm https://podcasts.apple.com/us/podcast/radically-genuine-podcast-with-dr-roger-mcfillin/id1573253801?i=1000624733618 Autism and Education https://www.fhautism.com/shop/autism-and-education-the-way-i-see-it-what-parents-and-teachers-need-to-know/ Thinking in Pictures https://www.grandin.com/inc/visual.thinking.html Autism and Intelligence and an Explanation https://www.youtube.com/watch?v=pxNg0xcadsM&t=316s (0:00) Intro; Autism and Education; Are Educators educated on Autism?; Biases from others towards the environment (7:00) The Prescription Era; Medication first Paradigm (10:32) The School Day- Conflicts with Criteria A and B; Limits a Capacity to Think; Underlying thoughts and feelings of agitation and frustration when learning; (13:15) Autism gives us the ability to be comfortable within ourselves; Are we like the so-called normal people, or not? (13:39) The Classroom- Social Dynamic, Speech and Language Dynamic, Sensory-Processing Dynamic, 3 strikes against Autism; (14:39) Subject Switching and Criteria B conflict (17:14) If you have met one child with Autism, you have met one child with Autism (17:49) Elementary School, 2 reasons why Reading is HARD, Social dynamic experience; (23:07) 4th Grade personal experience- easy task from the outside, tremendous difficulty for Autistics; (27:00) Art was fine, other subjects were not fine; Details to General versus General to Details; (27:58) High School personal experiences; Pathway to Success ＞ General Education; (29:52) Did I graduate, or Not? (31:56) SAT (32:43) Assessment Superpowers and Superdeficits- Very Superior to Severe/Impaired; Schools simply cannot accommodate to all- within group (Autistic to Autistic) or between group (Autistic to Masses) (36:34) Education Arrangement; Taking Notes is challenging (39:16) Wrap Up, Reviews, Ratings, Feedback, Contact Information

Do Antipsychotic Meds Prevent Awakening Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, we explore the often-overlooked phenomenon of antipsychotic withdrawal, examining new findings from the world's largest drug safety database. Could some cases of apparent psychotic relapse actually be withdrawal symptoms in disguise? We discuss common withdrawal effects, risk factors, and evidence-based strategies for safe medication discontinuation. Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 64 Antipsychotic Withdrawal Syndrome: Symptoms, Risks, and Prevention Strategies

In this episode, we speak with family and long-term care physician Sid Feldman about the KevinMD article "Antipsychotic use has been rising in long-term care homes, but we can do something about it." Sid shares how prescribing rates have surged to 24 percent in Canada, highlights the serious risks of antipsychotic medications, and emphasizes the importance of person-centered strategies. He also provides actionable ideas for addressing pain, encouraging staff education, and refocusing on holistic approaches that promote well-being for older adults living in long-term care. Our presenting sponsor is DAX Copilot by Microsoft. DAX Copilot, by Microsoft, is your AI assistant for automated clinical documentation and workflows. DAX Copilot allows physicians to do more with less and turn their words into a powerful productivity tool. DAX Copilot automates clinical documentation—making it available in the EHR within minutes—and clinical workflows, including referral letters, after-visit summaries, style and formatting customizations, and more. 70 percent of physicians who use DAX Copilot say it improves their work-life balance while reducing feelings of burnout and fatigue. Patients love it too! 93 percent of patients say their physician is more personable and conversational, and 75 percent of physicians say it improves patient experiences. Discover AI-powered solutions for clinical documentation and workflows. Click here to see a 12-minute DAX Copilot demo. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended GET CME FOR THIS EPISODE → https://www.kevinmd.com/cme I'm partnering with Learner+ to offer clinicians access to an AI-powered reflective portfolio that rewards CME/CE credits from meaningful reflections. Find out more: https://www.kevinmd.com/learnerplus

In this episode, we explore KarXT, a groundbreaking experimental antipsychotic that works through the cholinergic system rather than dopamine pathways. Could this novel approach revolutionize schizophrenia treatment by offering similar efficacy to current antipsychotics but without the motor side effects? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 63 Xanomeline-Trospium (KarXT) Shows Efficacy in Phase 3 Trial for Schizophrenia

In this episode, we explore the RADAR trial's findings on antipsychotic dose reduction in schizophrenia. Can patients with chronic schizophrenia safely reduce or discontinue their antipsychotic medications without increasing relapse risk? The trial's results challenge common assumptions about medication reduction and provide crucial guidance for clinical practice. Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 62 Antipsychotic Dose Reduction in Schizophrenia: Insights From the RADAR Trial  

In this episode, we explore the use of high-dose olanzapine as a potential alternative to clozapine for treatment-resistant schizophrenia. We discuss a systematic review that examines the efficacy and safety of olanzapine doses above the FDA-approved maximum. Could high-dose olanzapine be a viable option when patients refuse clozapine? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 61 Is High-Dose Olanzapine an Option for Treatment-Resistant Schizophrenia?

In this episode, we explore the cardiac and metabolic safety profile of antipsychotics in youth, based on a World Health Organization Safety Database analysis. We discuss age-dependent risks, specific medication concerns, and the importance of monitoring. How can clinicians balance the benefits of antipsychotics with potential cardiometabolic risks in young patients? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 20 Cardiac and Metabolic Safety Profile of Antipsychotics in Youth

A new med combo for alcohol use disorder, antipsychotic dose reduction in schizophrenia, and two new tips for using stimulants in ADHD.CME: Take the CME Post-Test for this EpisodePublished On: 10/28/2024Duration: 24 minutes, 12 secondsChris Aiken and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Very few people are willing and/or able to share and describe their descent into psychosis— in part because memory formation and consolidation are so impaired during episodes of psychosis…..and also because there is often so much fear and shame tied up in the experience of losing one's mind. Here Dr. H's  patient Corben describes his very early onset illness, how it started with years of depression,  then shifted into profound alienation and increasingly frightening psychosis, and finally into stability and recovery.BFTA on IG @backfromtheabysspodcasthttps://www.instagram.com/backfromtheabysspodcast/BFTA/ Dr. Hhttps://www.craigheacockmd.com/podcast-page/